Assyro AI

Title 21 CFR reference

Explore the full hierarchy of this title across chapters, subchapters, and parts.

Select a part from the tree to begin

Browse chapters and parts on the left to load sections

United States • Title 21 CFR • Part 511

Part 511PART 511—NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE

Part 511 outlines the conditions under which new animal drugs for investigational use are exempt from certain sections of the Federal Food, Drug, and Cosmetic Act, specifically focusing on drugs for in vitro/laboratory research and clinical investigations in animals.

What this part covers

  • Exemptions are provided for new animal drugs intended solely for in vitro tests or laboratory research animals, provided specific labeling and record-keeping requirements are met.
  • Clinical investigations in animals require labeling with specific caution statements, due diligence to prevent human use, and maintenance of adequate records.
  • Sponsors must submit a 'Notice of Claimed Investigational Exemption for a New Animal Drug' to the FDA, including drug identity, labeling, investigator information, and details on animal use, especially for food-producing animals.
  • Provisions are made for authorizing the use of edible products from treated food-producing animals, requiring data to ensure public health safety.
  • The FDA can request additional information and has the authority to terminate exemptions if conditions are not met or if the investigation is unsafe.
  • Disqualification procedures are detailed for clinical investigators who fail to comply with regulations or submit false information.
  • Sponsors are responsible for monitoring investigations, reporting adverse findings, and not commercially distributing the drug before approval.
  • Imported investigational drugs must meet specific conditions, including designation of a US agent or shipment to a qualified scientific institution.
  • Sponsors must submit environmental impact statements or claims for categorical exclusion.
  • Definitions and procedures for contract research organizations are included.

Sections in Part 511

§ 511.1

New animal drugs for investigational use exempt from section 512(a) of the Federal Food, Drug, and Cosmetic Act.

New animal drugs for tests in vitro and in laboratory research animals.(a) (1) A shipment or other delivery of a new animal drug or animal feed bearing or containing a new animal drug intended solely for tests in vitro or in animals used only for laboratory research purposes shall be exempt from section 512 (a) and (m) of the act if it is labeled as follows: (2) The person distributing or causing the distribution of new animal drugs for tests in vitro or in animals used only for laboratory research purposes under this exemption shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new animal drug will actually be used for tests in vitro or in animals used only for laboratory research. (3) The person who introduced such shipment or who delivered the new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the expert or expert organization to whom the new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. Upon the request of a…

§ 511.3

Definitions.

As used in this part: Contract research organization means a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor, e.g., design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to the Food and Drug Administration. Investigator means an individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. “Subinvestigator” includes any other individual member of that team. Sponsor means a person who takes responsibility for and initiates a clinical investigation. The sponsor may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual that uses one or more of its own employees to conduct an investigation that it has initiated is a…

Regulatory Context

This document sits within United States CFR and is most useful when linked to operational submission, quality, and inspection workflows.

United StatesCFR

Related Terms

Operational Use Cases

Related Actions